证券集体诉讼调查 - 律师事务所Faruqi & Faruqi正在调查Zenas BioPharma涉嫌违反联邦证券法的行为 投资者可在2025年6月16日前申请成为首席原告 [3] - 诉讼指控公司在IPO注册声明中存在虚假或误导性陈述 包括夸大现有资金和IPO净收益对运营的支撑时间 [5] - 当真实信息曝光后 投资者遭受损失 诉讼旨在追偿相关损失 [5] 投资者参与方式 - 在2024年9月13日左右通过IPO购买Zenas股票且损失超过7.5万美元的投资者可联系律所讨论法律权利 [1] - 首席原告需是拟议集体成员中财务利益最大且具代表性的投资者 但未担任首席原告仍可参与赔偿分配 [6] - 律所同时征集知情人士提供线索 包括举报人、前员工和股东等 [7] 律所背景 - Faruqi & Faruqi成立于1995年 在纽约、宾夕法尼亚等地设有办公室 累计为投资者追回数亿美元赔偿 [4] - 投资者可通过官网或电话877-247-4292获取Zenas集体诉讼详情 [8]

WASHINGTON, April 29, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC, a nationally prominent securities litigation firm, announces that retail and institutional investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the company's September 2024 initial public offering remain eligible to seek appointment as lead plaintiff in a securities class action lawsuit. The deadline to move for lead plaintiff is June 16, 2025. [Click here for information about j ...

NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statemen ...

诉讼背景 - 格罗斯律师事务所向在特定期间内购买Zenas BioPharma Inc (NASDAQ: ZBIO)股票的股东发布通知 [1] - 诉讼针对在2024年9月首次公开发行中购买或获得Zenas BioPharma证券的人士 [3] 指控内容 - 公司被指控在类别期间发布了 materially false and/or misleading statements [4] - 公司 materially overstated 使用现有现金和IPO预期净收益能够支撑运营的时间长度 [4] - 被告的公开声明在相关时间存在 materially false and misleading 且 negligently prepared [4] 程序信息 - 股东联系截止日期为2025年6月16日 [5] - 股东注册后将通过投资组合监控软件获得案件状态更新 [5] - 参与本案无需成本或义务 [5]

NEW YORK, April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=145066&from=4 CLASS PERIOD: This laws ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas’ registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click ...

文章核心观点 零售投资者若在Zenas BioPharma 2024年9月首次公开募股中购买股票且有损失，可考虑在2025年6月16日前申请成为证券集体诉讼的首席原告 [1][6] 案件情况 - 诉讼已在美国马萨诸塞州区联邦地方法院提起，指控Zenas BioPharma在首次公开募股注册文件中虚报财务状况 [4] - Zenas BioPharma称有足够资金运营24个月，但几周后第三季度财报显示资金仅够维持12个月 [4] - 自首次公开募股以来，Zenas BioPharma股价下跌近49%，从每股17美元降至2025年4月15日的8.72美元 [4] 首席原告相关 - 首席原告在诉讼中起积极作用，与律师合作代表所有集体成员利益，法院通常任命经济利益最大且能代表集体的投资者 [5] - 申请成为首席原告并非分享最终赔偿的必要条件，但可在诉讼中发声并参与制定策略 [6] 律所情况 - Cohen Milstein是美国领先的原告方律师事务所，专注证券诉讼和投资者保护 [7] - 该律所帮助股东追回数十亿美元赔偿，近期在富国银行证券诉讼案中追回10亿美元 [7] - 该律所及其律师被行业出版物评为美国最佳证券诉讼律师之一 [7]

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Zenas and certain of its o ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the fi ...

诉讼概述 - Levi & Korsinsky律所通知Zenas BioPharma Inc (NASDAQ: ZBIO)的投资者有关一项证券集体诉讼 [1] - 诉讼旨在为因涉嫌证券欺诈而遭受损失的投资者挽回损失 [2] 诉讼细节 - 指控被告作出虚假陈述和/或隐瞒事实，即Zenas BioPharma严重高估了其利用现有现金及首次公开募股(IPO)预期净收益能够维持运营的时间长度 [3] - 因此，被告的公开陈述在所有相关时间点均存在重大虚假和误导性，且为疏忽准备 [3] 诉讼参与信息 - 在相关时间段内遭受损失的投资者可在2025年6月16日前请求法院任命其为首席原告 [4] - 作为集体诉讼成员，可能有权获得补偿，无需支付任何自付费用 [4]